ChimeriVax-WN02 is a novel live-attenuated West Nile virus (WNV) vaccine containing modified WNV premembrane (prM) and envelope (E) sequences inserted into the yellow fever 17D vaccine genome. We investigated the induction and evolution of CD8 1 T cell responses to a WNV envelope epitope, which is a dominant target in naturally infected HLA-A*02-positive individuals. WNV epitope-specific CD8
In individuals vaccinated with chimeric WN/YF virus, we identified CD8
1 T cell responses directed against a WNV envelope epitope that is also an immunodominant T cell target in naturally infected individuals [18] [19] [20] . We employed tetramer staining to measure the magnitude and resilience of CD8 1 T cell responses to WNV envelope protein. We utilized phenotypic characteristics of memory phase T cells to examine the development of WNV envelope-specific T cells [21] [22] [23] [24] . Finally, we assessed the functional durability of the response by assessing cytotoxic potential and cytokine production following rechallenge with WNV envelope antigen in vitro.
MATERIALS AND METHODS

Study Design
The details of the Phase 1 study have been reported elsewhere [8] .
Volunteers were immunized with chimeric WN/YF at 2 different doses (3 log 10 plaque-forming units (PFUs) or 5 log 10 PFUs), YF-17D vaccine, or inert placebo. Blood samples obtained on days 0, 14, 28, 90, 180, and 360 after immunization were separated and then cryopreserved until use. Study protocols were approved by the institutional review boards of the participating centers.
Viruses
Construction of chimeric WN/YF virus has been described elsewhere [7] . In brief, the prM and E genes of the YF-17D vaccine strain were exchanged for those of the WNV NY-99 strain 385-99. Three attenuating mutations were introduced into the WNV E codon: E170 (leucine to phenylalanine), E336 (alanine to valine), and E440 (lysine to arginine). Serum viremia was measured by plaque assay [8] .
Construction of Recombinant Vaccinia Viruses
The WNV E sequence was amplified from the full-length WNV complementary DNA [25] by use of GeneAmp XL polymerase chain reaction (PCR; Applied Biosystems) and cloned into the donor vector pDONR221 by use of a PCR cloning system with Gateway Technology (Invitrogen). The vaccinia transfer plasmid pMJ601 was modified to facilitate insertion of the WNV E gene (Gateway Vector conversion system; Invitrogen). Recombinant vaccinia viruses were generated by homologous recombination and propagated in CV-1 cells [26] .
Generation of T Cell Lines
Peripheral blood mononuclear cells (PBMCs) were stimulated with chimeric WN/YF in the presence of 20% fetal calf serum and interleukin 7 (IL-7; 25 U/mL). Interleukin 2 (IL-2; 50 U/ mL) was added on day 3 and twice weekly thereafter. On day 7, T cell lines were screened in a chromium-release assay [27] . For generation of continuous T cell lines, limiting dilutions were performed on day 14. Cells were restimulated with anti-CD3 and c-irradiated allogeneic PBMCs every 14 days.
Cytotoxicity Assays
Epstein-Barr virus-transformed autologous B cell lines infected with recombinant vaccinia viruses expressing WNV E (VV-WNVE) were used as targets. For each sample, the specific lysis of targets infected with vaccinia viruses alone was subtracted from the specific lysis of targets infected with VV-WNVE. The specific lysis observed in pre-immunization samples was then subtracted as background. Values .10% above pre-immunization levels were considered positive. Overlapping WNV envelope peptides (Mimotopes) were also screened in a cytotoxicity assay that utilized peptide-coated target cells [28] . Major histocompatibility complex (MHC) restriction was determined using partially MHC-matched allogeneic target cells.
Peptides/Tetramers
An HLA-A*02-restricted epitope (SVGGVFTSV) from the WNV envelope protein residues 430-438 (referred to as E 430 ) was synthesized at >95% purity (Quality Controlled Biochemicals) and used to generate allophycocyanin-labeled E 430 / HLA-A*0201 tetramer complexes. Tetramers were titrated on a peptide-specific human T cell line.
Staining and Flow Cytometry
PBMCs were thawed, rested for 1 h, and stained with Live/Dead Aqua (Invitrogen 1 CD8 1 T cells in each of the 4 T cell subsets defined by CD45RA and CCR7 at serial time points after vaccination. Samples were analyzed on day 14 (n 5 13), day 28 (n 5 13), day 90 (n 5 13), day 180 (n 5 10), and day 360 (n 5 4). Triangles represent data from individual donors. Horizontal bars represent median values for each time point. The gating strategy is shown in Supplementary Figure 1A .
gated as shown in Supplementary Figure 1C . All flow cytometry reagents were obtained from BD Biosciences unless otherwise stated.
Statistical Analyses
Statistical analyses were performed using Prism software (version 5; GraphPad). Median values were calculated and comparisons between groups were performed using the MannWhitney U test. Correlation was calculated using the Spearman rank correlation coefficient. P values of ,.05 were considered statistically significant.
RESULTS
Recognition of an HLA-A*02-Restricted WNV Envelope Epitope by Chimeric WN/YF Vaccine Primed Cells
PBMCs from vaccinated donors were stimulated in vitro with chimeric WN/YF virus. Screening for recognition of WNV envelope peptides by cytotoxicity assay identified an HLA-A*02-restricted envelope epitope (SVGGVFTSV) at position E 430 . This epitope was concurrently identified by other groups using PBMCs from individuals naturally infected with WNV [18] [19] [20] . Given the high prevalence of donors with at least 1 HLA-A*02 allele in this study (49% of HLA typed donors), this epitope was selected for further study.
Kinetics of T Cell Epitope-Specific Responses to WNV E Peptide Following Vaccination
E 430 peptide/HLA-A*02 tetramer complexes were used to directly measure the kinetics of the response to WNV envelope in a subpopulation of 23 chimeric WN/YF virus-immunized HLA-A*02-positive donors ( Figure 1A ). We detected E 430 -specific responses by tetramer staining in 22 of 23 donors (Table 1) . CD3
1
CD8
1 T cells recognizing WNV E 430 increased markedly in the first month after vaccination and remained detectable throughout the first year after vaccination in the majority of donors. No statistically significant differences in tetramer frequencies were seen between individuals who received 3 log 10 PFUs and those who received 5 log 10 PFUs of vaccine (Table 1) , but the 3 individuals with the highest peak tetramer frequencies NOTE. Peripheral blood mononuclear cells (PBMCs) from recipients of ChimeriVax-WN02 who had at least 1 HLA-A*02 allele were stained ex vivo with West Nile virus envelope protein residues 430-438 (E 430 ) peptide/major histocompatibility complex tetramer at serial time points after immunization, as described in the Materials and Methods. The frequencies of CD3 1 CD8 1 tetramer-positive cells in each group were determined using the gating strategy shown in Supplementary Figure 1A . PBMCs from a single individual in the group that received 5 log 10 plaque-forming units (PFUs) of ChimeriVax-WN02 had no tetramer staining; PBMCs from all other subjects tested had detectable tetramer staining at >2 time points after immunization. Comparisons made between the tetramer frequencies measured in recipients of the 5 log 10 PFUs dose and those measured in the 3 log 10 PFUs dose group were analyzed using the Mann-Whitney U test. P values of <.05 were considered to be significant. We used WNV E 430 tetramer staining in conjunction with 2 markers commonly used to distinguish effector and memory subpopulations, CD45RA and CCR7 [29, 30] ( Figure 1B) . The most common phenotype of E 430 -specific cells in the first 2 weeks after immunization was CD45RA on day 28 (r 5 .725; 95% CI, .272-.915; P 5 .005) and day 90 (r 5 .610; 95% CI, .035-.881, P 5 .035). At 6-12 months after vaccination, 30%-40% of tetramer-positive cells were still positive for granzyme B, which suggests that the E 430 -specific memory T cell population may retain cytolytic function.
Perforin expression was substantially lower than granzyme B expression in E 430 -specific cells, with the proportion of perforinpositive cells peaking at a median of 22.4% (range, .7%-60.5%) on day 28 and declining to a median of 4.9% (range, 0%-15.7%) on day 360 (Figures 3D and 3F ). There was no significant difference between perforin expression during the effector response (days [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] and that during later memory time points (days 90-360).
Cytokine Response to WNV E 430 Peptide Restimulation Following Vaccination
In order to assess the ability of T cells primed with vaccine in vivo to produce cytokines upon rechallenge, PBMCs were Figure 4B ). By day 180, PBMCs from 7 of 12 donors (58.3%) produced detectable IFNc. PBMCs from few donors had detectable TNF-a production, and when it was present, it was usually seen in conjunction with other cytokines (Figures 4A and 4B) . Overall, the frequencies of E 430 -specific MIP-1ß-producing CD8 1 T cells were the highest 
DISCUSSION
Previous animal studies have demonstrated protection from WNV following immunization with chimeric WN/YF virus [7, 32] . Given the sporadic nature of WNV infection outbreaks, the evaluation of clinical efficacy of the vaccine in humans is challenging. Since CD8 1 T cell responses to WNV are critical for protection against neuroinvasive disease [10] [11] [12] [13] [14] , we evaluated the CD8 1 T cell response to chimeric WN/YF vaccine in human subjects as a potential immune correlate. E 430 has been identified as an immunodominant target in HLA-A*02-positive individuals who are naturally infected with WNV. Peptides containing the E 430 epitope stimulated IFN-c production in PBMCs from WNV viremic blood donors [18] as well as patients with symptomatic WNV disease [19, 20] . Mass spectrometry of peptides displayed by WNV-infected cells demonstrated natural processing of the E 430 epitope [19] . In addition, adoptive transfer of E 430 epitope-specific CD8 1 T cells into HLA-A*0201 transgenic mice conferred partial protection against lethal WNV challenge in the absence of preexisting antibody [33] . Our study is the first, to our knowledge, to use direct analysis of E 430 -specific T cells in humans by peptide-MHC tetramers. We were able to detect epitope-specific cells in 95.7% of donors tested. One of the attenuating mutations in the E gene of the chimeric WN/YF virus is at position 440, just outside the E 430 epitope. Despite the proximity of this mutation to E 430 , PBMCs from vaccinated HLA-A*02-positive individuals clearly recognized this epitope, as has been shown in PBMCs from individuals infected with wild-type WNV. E 430 is located in domain III of the WNV envelope; this region of WNV is considered important in virus neutralization [34, 35] .
Tetramer staining demonstrated the persistence of E 430 -specific CD8
1 T cells through the first year following vaccination with chimeric WN/YF virus. The peak frequency was seen on days 14-28 days in most vaccinees. This is slightly later than the reported 2 weeks for peak frequency of CD8 1 T cells expressing an activated phenotype after YF-17D vaccination [22] , but it is consistent with recent studies showing peak frequencies of CD8 1 T cells specific for yellow fever virus at 2-4 weeks after vaccination by tetramer staining [21, 24] . The duration of viremia was longer in subjects receiving chimeric WN/YF virus than in controls receiving YF-17D vaccination [8] . We previously showed in this cohort that a later peak of IFN-c by enzyme-linked immunospot assay as well as T cell proliferative responses to WNV antigen were correlated with a longer duration of viremia [8] . Here we similarly found a correlation between duration of viremia and the timing of peak E 430-tetramer-positive T cell frequency, suggesting that these E 430 -specific T cells aid control of viral replication. Alternatively, these findings may reflect the role of WNV antigen in driving expansion of antigen-specific T cells. Immunologic analyses from earlier viremic time points might help dissect elements of the CD8
1 T cell response that are responsible for resolution of viremia. The robust detection of WNV E 430 -specific cells during both the acute phase of the response to vaccination and in the months following allowed us to assess the evolution of their phenotype.
The YF-17D backbone in the vaccine construct increased the likelihood that the chimeric WN/YF virus would provide a broad, polyfunctional immune stimulus, which is believed to be one of the primary contributors to the success of YF-17D immunization [36, 37] . Given the recently published phenotypic profiling of yellow fever virus-specific CD8 1 T cells from acute and memory phases after vaccination [21, 22, 24] , we were able to assess the evolution of the response to WNV envelope antigen presented in a similar vaccine system. The majority of WNV E 430 -specific memory phase CD8 1 T cells were CD45RA 1 in samples from most donors, with approximately half of the antigen-specific memory phase T cells expressing the lymph node homing marker CCR7. A high proportion of antigen-specific CD45RA 1 memory phase T cells was also seen in samples from individuals vaccinated with YF-17D and vaccinia viruses [21, 22, 24] ; these cells were able to proliferate and produce cytokines in response to in vitro viral antigen restimulation, despite the fact that CD45RA 1 memory cells were previously believed to be terminally differentiated [22, 24] . The IL-7 receptor a-chain (CD127) is a marker of CD8 1 T cells persisting into memory [31] . High levels of CD127 reexpression have been shown in vaccinia-specific CD8 1 T cells at 6-12 months after immunization [22, 38] and in YF-specific CD8
1 T cells at up to 2 years after immunization [24] . The kinetics of CD127 expression on HLA-A*02-restricted WNV envelopespecific T cells is similar to those demonstrated for a YF NS4b epitope in HLA-A*02-positive YF-immunized subjects [24] . In our studies, 75% of WNV envelope-specific T cells on average expressed CD127 at 6-12 months after vaccination, suggesting these cells have the ability to persist as long-term memory T cells and may provide protection over extended periods. The majority of WNV envelope-specific CD8 1 T cells expressed granzyme B at the peak of the acute response; high levels of granzyme B expression in antigen-specific CD8 1 T cells were also seen 1 month after vaccinia and YF-17D immunizations [24, 39] . In our study, the degree of target cell lysis observed upon in vitro restimulation correlated with the proportion of E 430 -specific cells expressing granzyme B directly ex vivo at 1 and 3 months after vaccination. In addition, 30%-40% of WNV E 430 -specific CD8 1 T cells retained granzyme B expression in the memory phase; similar frequencies of granzyme B-expressing antigen-specific CD8 1 T cells have been observed 1 year after vaccinia immunization [39] . Cytokine production following in vitro restimulation was seen in the majority of donors tested by day 28 after immunization with chimeric WN/YF virus. However, the frequency of cells producing IFN-c, MIP-1ß, and/or TNF-a following in vitro E 430 peptide stimulation was lower than the frequency of cells binding E 430 tetramer ex vivo. A similar discrepancy between the frequency of CD8 1 T cells binding peptide/MHC and those producing cytokines in response to peptide stimulation was observed following YF-17D immunization [21] . Samples obtained during the acute phase of the immune response may contain activated cells refractory to further antigenic stimulation [40] . Alterntively, some E 430 -specific CD8 1 T cells may have expressed other cytokines, such as IL-2, which were not measured in this study. These results demonstrate that immunization with WNV envelope antigen presented in the context of the YF-17D backbone elicits a robust and durable WNV envelope-specific CD8
1
T cell response to a naturally processed HLA-A*02-restricted epitope that is immunodominant in WNV-infected individuals. Our analyses using a WNV envelope-specific tetramer demonstrate that these cells possess characteristics in common with high-quality memory T cells generated by other live attenuated vaccines [21-24, 38, 39] . These studies are limited to the analysis of a single epitope, albeit one that has emerged consistently in studies of HLA-A*02-positive individuals who are naturally infected with WNV. Because one of the hallmarks of the response to YF-17D immunization is the breadth of the response [24, 28] , study of additional vaccine epitopes, including those in the YF-17D backbone, would help further define the CD8 1 T cell response to this unique vaccine system. 
